► 
► 
► 
► 
► 
► 
► 
4.1.8 
4.1.9 
4.1.10 
surface antigen (HBsAG) test prior to study entry. Patients may 
not enter the study if HBsAG is positive.] 
PT and PTT not more than 1.5 times the ULN 
Hemoglobin >.9.0 g/dl (patients cannot be transfusion dependent) 
Platelets _>_ 75,000/mm 3 
WBC > 2,000/mm 3 
Absolute Neutrophil Count (ANC) J> 1,000/mm 3 
Serum Amylase < 1.5 times the ULN 
Bilirubin <. 2.5 mg/dL 
Ability to give informed consent 
Normal cardiac function by history and exam 
Kamofsky Performance Status >_ 40 
4.2 Exclusion Criteria 
Patients who meet any one of the following criteria will be excluded from study 
entry: 
4.2.1 Pregnant or lactating females [all patients must practice adequate birth 
control and females of child-bearing potential must have a negative serum 
beta-HCG pregnancy test (within Day -7 to Day 0)]. 
4.2.2 Acute infection: any acute viral, bacterial, or fungal infection which 
requires specific therapy. Acute therapy must have been completed within 
14 days prior to study treatment. 
4.2.3 Hepatitis-B surface antigen positive patients. 
4.2.4 HIV-infected patients. 
4.2.5 Acute medical problems such as ischemic heart or lung disease that may 
be considered an unacceptable anesthetic or operative risk. 
4.2.6 Patients with any underlying conditions which would contraindicate 
therapy with study treatment (or allergies to reagents used in this study). 
4.2.7 Patients with organ allografts 
[424] 
Recombinant DNA Research, Volume 18 
